Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
gpASIT+ in Seasonal Allergic Rhinoconjunctivitis
NCT00833066Phase 2Completed
- Sponsor
- TOOLS Life Science
- Start
- Feb 2009
- Primary completion
- Oct 2009
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of gpASIT+ in Seasonal Allergic Rhinoconjunctivitis (SAR) (4 arms), sponsored by TOOLS Life Science. Primary endpoint: Evidence of allergic reaction at 14 days. Started Feb 2009; status: completed.
02
Drugs
gpASIT+
03
Conditions
Seasonal Allergic Rhinoconjunctivitis (SAR)
Beyond the preview
Go deeper on NCT00833066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00833066.